Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses.
As SARS-CoV-2 Omicron and other variants of concern (VOCs) continue spreading worldwide, development of antibodies and vaccines to confer broad and protective activity is a global priority. Here, we report on the identification of a special group of nanobodies from immunized alpaca with potency against diverse VOCs including Omicron subvariants ... BA.1, BA.2 and BA.4/5, SARS-CoV-1, and major sarbecoviruses. Crystal structure analysis of one representative nanobody, 3-2A2-4, discovers a highly conserved epitope located between the cryptic and the outer face of the receptor binding domain (RBD), distinctive from the receptor ACE2 binding site. Cryo-EM and biochemical evaluation reveal that 3-2A2-4 interferes structural alteration of RBD required for ACE2 binding. Passive delivery of 3-2A2-4 protects K18-hACE2 mice from infection of authentic SARS-CoV-2 Delta and Omicron. Identification of these unique nanobodies will inform the development of next generation antibody therapies and design of pan-sarbecovirus vaccines.
Mesh Terms:
Angiotensin-Converting Enzyme 2, Animals, Antibodies, Neutralizing, Antibodies, Viral, COVID-19, Camelids, New World, Mice, SARS-CoV-2, Severe acute respiratory syndrome-related coronavirus, Single-Domain Antibodies, Spike Glycoprotein, Coronavirus
Angiotensin-Converting Enzyme 2, Animals, Antibodies, Neutralizing, Antibodies, Viral, COVID-19, Camelids, New World, Mice, SARS-CoV-2, Severe acute respiratory syndrome-related coronavirus, Single-Domain Antibodies, Spike Glycoprotein, Coronavirus
Nat Commun
Date: Dec. 27, 2022
PubMed ID: 36575191
View in: Pubmed Google Scholar
Download Curated Data For This Publication
243274
Switch View:
- Interactions 2